DGAP-News: HAEMATO AG: 2013: Preliminary IFRS results, sales of EUR 174.6 million, annual net income of EUR 8.2 million; confirmation of dividend policy

        Print
| Source: EQS Group AG
DGAP-News: HAEMATO AG / Key word(s): Preliminary Results/Final Results
HAEMATO AG: 2013: Preliminary IFRS results, sales of EUR 174.6
million, annual net income of EUR 8.2 million; confirmation of
dividend policy

21.02.2014 / 12:48

---------------------------------------------------------------------

Corporate News of HAEMATO AG: 
2013: Preliminary IFRS results, sales of EUR 174.6 million, annual net
income of EUR 8.2 million; confirmation of dividend policy

In the financial year 2013 HAEMATO AG, Berlin (ISIN: DE0006190705),
achieved IFRS Group sales of EUR 174.6 m (previous year: EUR 25.0 m) and
profit of EUR 8.2 m (previous year: EUR 7.4 m; thereof non-recurring profit
from sales of property of EUR 7.3 m).

In the fourth quarter the IFRS Group sales amounted to EUR 56.3 m and
earnings reached EUR 2.1 m.

As a result of the initial consolidation during the fiscal year, the first
quarter 2013 of HAEMATO PHARM GmbH's total annual turnover of EUR 217 m is
not included in the consolidated financial statements of HAEMATO. Sales and
earnings contributions of HAEMATO PHARM GmbH are included with the second,
third and fourth quarter 2013.

"HAEMATO AG has the potential for further growth of the pharmaceuticals
business, which is characterized by stable cash flows. On the basis of the
visibility of the profit we can reconfirm the established dividend policy",
says Dr. Christian Pahl, Member of the Management Board of HAEMATO AG.

About HAEMATO:

HAEMATO AG was founded in 1993 and is a stock exchange quoted
pharmaceutical company. The company is listed on the Frankfurt Stock
Exchange in the Entry Standard (Open Market) and is based in Schönefeld,
Germany.

The focus of the business activities lies on the growth markets of patent
free and patent protected medicinal products. Focal points are therapies
with cancer, HIV, cardiovascular and other chronic diseases.


Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir@haemato.de


End of Corporate News

---------------------------------------------------------------------

21.02.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


253686 21.02.2014